Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03626-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Zhipeng Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, 200003, Shanghai, China. Hauptthemen laut MEDLINE: Hypothyroidism, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 106 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, the Shanghai Municipal Health Commission, Jin-Zi-Ta Talent projects of Shanghai Changzheng Hospital, China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, 200003, Shanghai, China.
- Institute of Basic Medicine and Cancer (IBMC), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- College of Traditional Chinese Medicine, Yunnan University of Traditional Chinese Medicine, Kunming, 650500, Yunnan, China.
- Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, 200003, Shanghai, China. gaoshouhong@smmu.edu.cn.
- Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, 200003, Shanghai, China. chenwansheng@smmu.edu.cn.
- Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, 200003, Shanghai, China. taoxia2003@126.com.
Förderung
- the National Natural Science Foundation of China
- the Shanghai Municipal Health Commission
- Jin-Zi-Ta Talent projects of Shanghai Changzheng Hospital, China
- Clinical Medical Technology Incubation Project of Shanghai Changzheng Hospital
Zitieren
APA
Wang, Z., Wang, H., Bu, C., Meng, B., Mu, Y., Gao, S., Chen, W., & Tao, X. (2024). Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03626-4
Vancouver
Wang Z, Wang H, Bu C, Meng B, Mu Y, Gao S, et al. Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03626-4
BibTeX
@article{Wang2024,
author = {Wang, Zhipeng and Wang, Hongsen and Bu, Chen and Meng, Bosu and Mu, Yuhui and Gao, Shouhong and Chen, Wansheng and Tao, Xia},
title = {Tyrosine kinase inhibitor–induced hypothyroidism: mechanism and clinical implications},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03626-4}
}
EUVIMED